The Global Insulin Delivery Devices Market Size is projected to grow at a CAGR of 8.6% during the forecast period from 2026 to 2034 | DelveInsight

The Insulin Delivery Devices market is estimated at USD 20.4 billion in 2025 and is projected to reach USD 42.8 billion by 2034. Growth is anchored in the rising global prevalence of diabetes, the accelerating shift toward automated insulin delivery and closed-loop systems, and the growing adoption of smart and connected insulin pens.
DelveInsight's Insulin Delivery Devices Market Insights Report 2034 provides the current and forecast market analysis, individual leading Insulin Delivery Devices companies' market shares, challenges, Insulin Delivery Devices Market Drivers, barriers, trends, and key market Insulin Delivery Devices companies in the market.

To read more about the latest highlights related to the Insulin Delivery Devices Market @ https://www.delveinsight.com/sample-request/insulin-delivery-devices-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Key Takeaways from the Insulin Delivery Devices Market Report
• In 2026, Eli Lilly discontinued its Tempo Pen smart insulin pen. Strategic significance: Signals a strategic recalibration within the smart pen category and underscores the commercial challenges of sustaining standalone connected pen hardware against larger, more established competitors.
• In July 2025, Medtronic received CE Mark approval to expand the indicated population for its MiniMed 780G automated insulin delivery system to include individuals as young as two years old, pregnant women, and people with insulin-requiring type 2 diabetes. Strategic significance: Broadens Medtronic's addressable AID market beyond its historical type 1 diabetes core base.
• In May 2025, GO-Pen ApS received FDA 510(k) clearance for the GO-PEN, a user-filled reusable insulin pen compatible with standard insulin vials. Strategic significance: Introduces a more affordable and sustainable alternative to traditional prefilled disposable pens.
• The global Insulin Delivery Devices market is growing at a CAGR of 8.6% during the forecast period from 2026 to 2034.
• The principal drivers are the rising global prevalence of diabetes; the accelerating shift toward automated insulin delivery (AID) and closed-loop systems; the growing adoption of smart and connected insulin pens; expanding regulatory indications to insulin-requiring type 2 diabetes, pregnancy, and pediatric populations; and the rising preference for home-based diabetes management.
• By product type, the insulin pens segment dominated the market with a 43% share in 2025, while North America accounted for the largest regional share at 36% and Asia-Pacific is anticipated to register the fastest growth through 2034.
• The leading Insulin Delivery Devices Companies include Medtronic plc, Insulet Corporation, Tandem Diabetes Care, Inc., Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Ypsomed Holding AG, Becton, Dickinson and Company, Beta Bionics, Inc., and Terumo Corporation, among others.

To know more about why North America is leading the market growth in the Insulin Delivery Devices Market, Get a snapshot @ https://www.delveinsight.com/sample-request/insulin-delivery-devices-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Insulin Delivery Devices Overview
Insulin delivery devices are medical tools used to administer insulin to people with diabetes, since insulin cannot be taken orally and must be delivered into subcutaneous tissue. The scope encompasses insulin pens (reusable, disposable prefilled, and smart or connected), insulin pumps (tethered or durable and patch or tubeless), automated insulin delivery systems that bundle a pump, continuous glucose monitor, and dosing algorithm, insulin syringes, and insulin jet injectors and other needle-free delivery systems. These devices are used across homecare, hospital, and diabetes clinic settings for both type 1 and type 2 diabetes populations.
Insulin Delivery Devices Market Key Growth Drivers
• The rising global prevalence of diabetes, with an estimated 591 million people living with diabetes in 2025 and a figure projected to approach 854 million by 2050, is sustaining broad-based demand for insulin administration devices. More than 90% of cases are type 2 diabetes, and a growing share of this population requires insulin as oral medications become insufficient.
• The accelerating shift toward automated insulin delivery and closed-loop systems is reshaping the market. Systems including Medtronic's MiniMed 780G, Insulet's Omnipod 5, Tandem's Control-IQ+ platform, and Beta Bionics' iLet Bionic Pancreas integrate continuous glucose monitoring data with dosing algorithms to reduce the burden of manual dosing and improve time-in-range outcomes. In March 2024, the FDA cleared the Sequel Twiist AID system, the first to directly measure the volume and flow of delivered insulin.
• Growing adoption of smart and connected insulin pens, such as Medtronic's InPen, Novo Nordisk's NovoPen 6 and NovoPen Echo Plus, and the Mallya connected pen cap acquired through Novo Nordisk's 2023 acquisition of Biocorp, is extending dose logging, insulin-on-board calculation, and CGM integration to patients on multiple daily injections.
• Expanding regulatory indications are broadening the eligible patient base, as exemplified by Medtronic's July 2025 CE Mark expansion for the MiniMed 780G to include children as young as two, pregnant women, and people with insulin-requiring type 2 diabetes.
• The rising preference for home-based diabetes management favors self-administered, discreet, and connected devices, reducing the need for frequent clinical visits while enabling remote monitoring by healthcare providers.
• Ongoing product innovation and competitive launch activity, including Tandem's February 2024 launch of the Tandem Mobi and Insulet's April 2024 Health Canada approval of Omnipod 5, sustains replacement and upgrade-driven demand.
• The convergence of automation, connectivity, expanding indications, and rising disease burden is expected to sustain strong growth in the market through 2034.

Get a sneak peek at the Insulin Delivery Devices Market Dynamics @ https://www.delveinsight.com/sample-request/insulin-delivery-devices-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Insulin Delivery Devices Market Segment Analysis
The Insulin Delivery Devices market is segmented by Product Type (Insulin Pens [Reusable, Disposable/Prefilled, and Smart/Connected], Insulin Pumps [Tethered/Durable and Patch/Tubeless], Insulin Syringes, Insulin Jet Injectors, and Others), System Type (Automated Insulin Delivery/Closed-Loop Systems and Conventional/Open-Loop Insulin Delivery), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), End-User (Homecare Settings, Hospitals, Diabetes and Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of World).
In 2025, insulin pens held a 43% share by product type, type 2 diabetes accounted for 58% by diabetes type, and homecare settings led with a 66% share by end-user. Conventional open-loop delivery held the largest share by system type, while AID systems were the fastest-growing.

Insulin Delivery Devices Market Competitive Landscape
The Insulin Delivery Devices market is classified as Consolidated. A small group of established medical technology and pharmaceutical companies, including Medtronic, Insulet, Tandem Diabetes Care, Novo Nordisk, Sanofi, Eli Lilly, Roche, and Ypsomed, holds the majority of the market through comprehensive portfolios spanning pens, pumps, and AID systems, supported by digital platforms that connect devices to mobile applications and cloud-based data systems. Medtronic and Insulet lead in automated insulin delivery through the MiniMed 780G and Omnipod 5, Tandem leads in tethered pump miniaturization through the Tandem Mobi, Novo Nordisk, Eli Lilly, and Sanofi lead in global insulin pen volume, and Beta Bionics leads in autonomous, algorithm-driven closed-loop delivery through the iLet Bionic Pancreas. Specialist and regional vendors such as Becton Dickinson, Terumo, Abbott, CeQur, and EOFLOW compete through focused device categories, CGM partnerships, and patch pump innovation.
Which MedTech key players in the Insulin Delivery Devices Market are set to emerge as the trendsetter explore @ https://www.delveinsight.com/sample-request/insulin-delivery-devices-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Insulin Delivery Devices Companies
Medtronic plc, Insulet Corporation, Tandem Diabetes Care, Inc., Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Ypsomed Holding AG, Becton, Dickinson and Company, Beta Bionics, Inc., Terumo Corporation, and others.

Insulin Delivery Devices Market Restraints
Despite strong momentum, the Insulin Delivery Devices market faces several constraints. The continued availability and effectiveness of oral antidiabetic medications delays the transition to injectable or pump-based insulin therapy for many type 2 diabetes patients. An increased number of device-related product recalls has raised safety and reliability concerns among patients, clinicians, and regulators. High device and consumable costs, combined with limited reimbursement in many geographies outside North America and Western Europe, constrain adoption of advanced pumps, AID systems, and smart pens, while recently implemented U.S. tariffs on imported medical devices and components have raised production costs for manufacturers reliant on global supply chains. The steep learning curve of advanced pump and AID technology can limit adoption among older patients, and the lack of full interoperability between devices from different manufacturers continues to limit patient choice and system flexibility.

Interested in knowing the Insulin Delivery Devices Market by 2034? Click to get a snapshot of the Insulin Delivery Devices Market Trends- https://www.delveinsight.com/sample-request/insulin-delivery-devices-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Scope of the Insulin Delivery Devices Market Report
• Coverage- Global
• Forecast Period- 2026-2034
• Insulin Delivery Devices Companies- Medtronic plc, Insulet Corporation, Tandem Diabetes Care, Inc., Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Ypsomed Holding AG, Becton, Dickinson and Company, Beta Bionics, Inc., Terumo Corporation, and others.
• Insulin Delivery Devices Market Restraints and Regulatory Analysis
• Insulin Delivery Devices Porter Five Forces Analysis and Market Assessment

Explore more information of the Insulin Delivery Devices Market Insights @ https://www.delveinsight.com/sample-request/insulin-delivery-devices-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Table of Contents
1. Insulin Delivery Device Market Introduction
2. Insulin Delivery Device Market Executive Summary
3. Insulin Delivery Device Market Key Factors Analysis
4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
5. Regulatory Analysis
6. Insulin Delivery Device Market Porter's Five Forces Analysis
7. Insulin Delivery Device Market Assessment
8. Insulin Delivery Device Market Competitive Landscape
9. Insulin Delivery Device Market Startup Funding and Investment Trends
10. Insulin Delivery Device Market Company and Product Profiles
11. Insulin Delivery Device Report KOL Views
12. Project Approach
13. About DelveInsight
14. Disclaimer and Contact Us

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.